DRESS syndrome : Part I. Clinical perspectives - 18/04/13
Abstract |
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also referred to as drug-induced hypersensitivity syndrome, is a distinct, potentially life-threatening adverse reaction. It is seen in children and adults most often as a morbilliform cutaneous eruption with fever, lymphadenopathy, hematologic abnormalities, and multiorgan manifestations. Historically, it was most frequently linked with phenytoin and known as phenytoin hypersensitivity syndrome. However, because many other medications were found to produce the same reaction, another name was in order. Anticonvulsants and sulfonamides are the most common offending agents. Its etiology has been linked with lymphocyte activation, drug metabolic enzyme defects, eosinophilia, and human herpesvirus-6 reactivation. DRESS has a later onset and longer duration than other drug reactions, with a latent period of 2 to 6 weeks. It may have significant multisystem involvement, including hematologic, hepatic, renal, pulmonary, cardiac, neurologic, gastrointestinal, and endocrine abnormalities. This syndrome has a 10% mortality rate, most commonly from fulminant hepatitis with hepatic necrosis.
Le texte complet de cet article est disponible en PDF.Key words : DRESS syndrome, drug allergy, drug-induced hypersensitivity syndrome, eosinophilia, erythroderma, phenytoin hypersensitivity, severe drug eruption, toxic epidermal necrolysis
Abbreviations used : ANEM, CMV, CYP-450, EBV, DIHS, DRESS, HHV, J-SCAR, T4
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
|
Reprints not available from the authors. |
Vol 68 - N° 5
P. 693.e1-693.e14 - mai 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?